Merck's Gardasil 9 launches in Canada; Immunomic wins NIH grant for peanut allergy candidate;

> Merck's ($MRK) Gardasil 9 has launched in Canada. Release

> Immunomic Therapeutics has won a Small Business Innovation Research grant from the NIH for its work on a peanut allergy vaccine. Release

> Diabetes vaccine maker Diamyd Medical has received 15 million Swedish krona ($1.7 million) in a direct issue. Release

> The human vaccine market in China is slated to jump as R&D and production capacity grow. Release

And Finally... Geovax has assigned a trial number to the next study of its candidate HIV preventive. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.